Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nxera Pharma UK Limited
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics in young and elderly healthy volunteers of HTL9936, a selective M1 receptor agonist intended for the treatment of cognitive disorders. This study is a single ascending dose study.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Body mass index of ≥19 and ≤ 30kg/m²
Healthy subject free from any clinically significant illness or disease
Female subjects must be ≥65 years
You may not be if
Subject who is predicted to be a CYP2D6 poor or ultra rapid metabolizer
History of hypersensitivity to study drug
History of epilepsy or seizures
Subject with previous history of suicidal behavior
